Omeros has been rising since the open of trade Wednesday and is now up 1.38 at $21.54 on above average volume. The stock has climbed to nearly a 3-month high.
If the stock closes at or above $15 at expiration this trade will return 7.91% or 21.71% (for comparison purposes only). OMER closed Jan 4, 2018's trading session at $19.70. In the past year, the stock has hit a 52-week low of $8.71 and …
Shares of Omeros Corporation (NASDAQ: OMER) surged nearly 17% on Tuesday after the company announced that the U.S. Food and Drug Administration had granted its lead drug candidate breakthrough therapy designation. OMS721 is …
One of Omeros' competitors within the Biotechnology space, Halozyme Therapeutics, Inc. (NASDAQ: HALO), reported …
The lead candidate in clinical trials for Omeros, OMS721 is a unique drug that appears to prevent blood cell damage responsible for a range of rare disorders. On Monday, the company announced seven patients withatypical hemolytic …
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ ... “Art Doyle,” an entity or group that self-identifies as having a short position in Omerosstock. Because of its ongoing legal action, including a number of steps aimed at …
Omer said: “We envision that individuals ... optimise fleet routes and reduce misplaced stock.” The team are now conducting 3 pilots with warehouses in UK, …
No one is taking the moribund contracts of Omer Asik and Alexis Ajinca without …
ESPN11d
LONDON, UK / ACCESSWIRE / May 18, 2017 / Active Wall St. blog coverage looks at the headline from Omeros Corp. …